VIEWPOINT
The Forgotten Majority
Unfinished Business in Cardiovascular Risk Reduction
Peter Libby, MD*
Donald W. Reynolds Cardiovascular Clinical Research Center, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts.
Manuscript received February 4, 2005;
accepted February 16, 2005.
* Reprint requests and correspondence: Dr. Peter Libby, Brigham and Women’s Hospital, 77 Avenue Louis Pasteur, NRB 741, Boston, Massachusetts 02115. (Email: plibby{at}rics.bwh.harvard.edu).
Despite meaningful progress in the identification of risk factors and the development of highly effective clinical tools, deaths from cardiovascular disease continue to increase worldwide. Sparked by an obesity epidemic, the metabolic syndrome and the rising incidence of type 2 diabetes have led to an upsurge of cardiovascular risk. Although pharmacologic treatments with the statin class of drugs have reduced cholesterol levels and lowered mortality rates, several large controlled clinical trials, including the Scandinavian Simvastatin Survival Study, the Cholesterol and Recurrent Events trial, the Air Force/Texas Coronary Atherosclerosis Prevention studies, and Long-term Intervention with Pravastatin in Ischemic Disease study, have indicated that cardiovascular events continue to occur in two thirds of all patients. Follow-up studies, such as the Heart Protection Study and the Pravastatin or Atorvastatin Evaluation and Infection Therapy/Thrombolysis In Myocardial Infarction-22 trials, reinforced these earlier results. Although therapy with gemfibrozil, a fibric acid derivative, showed reduced occurrence of cardiovascular events in the Helsinki Heart Study and the Veterans Affairs HDL Intervention Trial, results of other studies, e.g., the Bezafibrate Intervention Program and the Diabetes Atherosclerosis Intervention study, showed less encouraging results. Although lifestyle modifications, such as improved diet and increased exercise levels, benefit general health and the metabolic syndrome and insulin resistance in particular, most people continue to resist changes in their daily routines. Thus, physicians must continue to educate their patients regarding an optimal balance of drug therapy and personal behavior.
|
Abbreviations and Acronyms
| | HDL = high-density lipoprotein | | HMG-CoA = 3-hydroxy-3-methlyglutaryl coenzyme A | | LDL = low-density lipoprotein |
|
This article has been cited by other articles:
|
|
|
|
 
S. J. Nicholls, H. B. Brewer, J. J. P. Kastelein, K. A. Krueger, M.-D. Wang, M. Shao, B. Hu, E. McErlean, and S. E. Nissen
Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol: A Randomized Controlled Trial
JAMA,
November 16, 2011;
306(19):
2099 - 2109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Bucerius, R. Duivenvoorden, V. Mani, C. Moncrieff, J. H. F. Rudd, C. Calcagno, J. Machac, V. Fuster, M. E. Farkouh, and Z. A. Fayad
Prevalence and Risk Factors of Carotid Vessel Wall Inflammation in Coronary Artery Disease Patients: FDG-PET and CT Imaging Study
J. Am. Coll. Cardiol. Img.,
November 1, 2011;
4(11):
1195 - 1205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Hermans and J.-C. Fruchart
Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians
Therapeutic Advances in Chronic Disease,
September 1, 2011;
2(5):
307 - 323.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Ohshiro, D. Matsuda, K. Sakai, C. Degirolamo, H. Yagyu, L. L. Rudel, S. Omura, S. Ishibashi, and H. Tomoda
Pyripyropene A, an Acyl-Coenzyme A:Cholesterol Acyltransferase 2-Selective Inhibitor, Attenuates Hypercholesterolemia and Atherosclerosis in Murine Models of Hyperlipidemia
Arterioscler Thromb Vasc Biol,
May 1, 2011;
31(5):
1108 - 1115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hartmann, J. Huisman, D. Bose, L. O. Jensen, P. Schoenhagen, G. S. Mintz, R. Erbel, and C. von Birgelen
Serial intravascular ultrasound assessment of changes in coronary atherosclerotic plaque dimensions and composition: an update
Eur Heart J Cardiovasc Imaging,
April 1, 2011;
12(4):
313 - 321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Fryburg and M. T. Vassileva
Atherosclerosis Drug Development in Jeopardy: The Need for Predictive Biomarkers of Treatment Response
Science Translational Medicine,
March 2, 2011;
3(72):
72cm6 - 72cm6.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Nicholls, A. Gordon, J. Johansson, K. Wolski, C. M. Ballantyne, J. J. P. Kastelein, A. Taylor, M. Borgman, and S. E. Nissen
Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease: A Randomized Controlled Trial
J. Am. Coll. Cardiol.,
March 1, 2011;
57(9):
1111 - 1119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kones
Is prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention
Therapeutic Advances in Cardiovascular Disease,
February 1, 2011;
5(1):
61 - 81.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Kones
Low-Fat Versus Low-Carbohydrate Diets, Weight Loss, Vascular Health, and Prevention of Coronary Artery Disease: The Evidence, the Reality, the Challenge, and the Hope
Nutr Clin Pract,
October 1, 2010;
25(5):
528 - 541.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Marz, A. Meinitzer, C. Drechsler, S. Pilz, V. Krane, M. E. Kleber, J. Fischer, B. R. Winkelmann, B. O. Bohm, E. Ritz, et al.
Homoarginine, Cardiovascular Risk, and Mortality
Circulation,
September 7, 2010;
122(10):
967 - 975.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Nicholls, P. Lundman, and J.-C. Tardif
Diabetic dyslipidemia: extending the target beyond LDL cholesterol
European Journal of Cardiovascular Prevention & Rehabilitation,
May 1, 2010;
17(1_suppl):
s20 - s24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Harper and T. A. Jacobson
Using Apolipoprotein B to Manage Dyslipidemic Patients: Time for a Change?
Mayo Clin. Proc.,
May 1, 2010;
85(5):
440 - 445.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Chapman, W. Le Goff, M. Guerin, and A. Kontush
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
Eur. Heart J.,
January 2, 2010;
31(2):
149 - 164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. A. Jaffer
Assessing Niacin as an Atherosclerosis Therapeutic Agent: Valuable Insights Provided by High-Resolution Vascular Magnetic Resonance Imaging
J. Am. Coll. Cardiol.,
November 3, 2009;
54(19):
1795 - 1796.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Terre
Advancing the Prevention and Control of Hypertension
American Journal of Lifestyle Medicine,
November 1, 2009;
3(6):
450 - 453.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. R. Meyer and M. Barton
ER{alpha}, ER{beta}, and gpER: novel aspects of oestrogen receptor signalling in atherosclerosis
Cardiovasc Res,
September 1, 2009;
83(4):
605 - 610.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Seth Loomba and R. Arora
Fibrates: where are we now?
Therapeutic Advances in Cardiovascular Disease,
February 1, 2009;
3(1):
91 - 96.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Papaliodis, W. Boucher, D. Kempuraj, M. Michaelian, A. Wolfberg, M. House, and T. C. Theoharides
Niacin-induced "Flush" Involves Release of Prostaglandin D2 from Mast Cells and Serotonin from Platelets: Evidence from Human Cells in Vitro and an Animal Model
J. Pharmacol. Exp. Ther.,
December 1, 2008;
327(3):
665 - 672.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Steinberg, C. K. Glass, and J. L. Witztum
Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia
Circulation,
August 5, 2008;
118(6):
672 - 677.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Thorp, D. Cui, D. M. Schrijvers, G. Kuriakose, and I. Tabas
Mertk Receptor Mutation Reduces Efferocytosis Efficiency and Promotes Apoptotic Cell Accumulation and Plaque Necrosis in Atherosclerotic Lesions of Apoe-/- Mice
Arterioscler Thromb Vasc Biol,
August 1, 2008;
28(8):
1421 - 1428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Koenig
Treating Residual Cardiovascular Risk: Will Lipoprotein-Associated Phospholipase A2 Inhibition Live Up to Its Promise?
J. Am. Coll. Cardiol.,
April 29, 2008;
51(17):
1642 - 1644.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Barton, R. Minotti, and E. Haas
Inflammation and Atherosclerosis
Circ. Res.,
October 12, 2007;
101(8):
750 - 751.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Windler, M. Schoffauer, and B.-C. Zyriax
The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease
Diabetes and Vascular Disease Research,
June 1, 2007;
4(2):
136 - 142.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. E. Nissen, S. J. Nicholls, K. Wolski, D. C. Howey, E. McErlean, M.-D. Wang, E. V. Gomez, and J. M. Russo
Effects of a Potent and Selective PPAR-{alpha} Agonist in Patients With Atherogenic Dyslipidemia or Hypercholesterolemia: Two Randomized Controlled Trials
JAMA,
March 28, 2007;
297(12):
1362 - 1373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Cubbon, S. B. Wheatcroft, P. J. Grant, C. P. Gale, J. H. Barth, R. J. Sapsford, R. Ajjan, M. T. Kearney, A. S. Hall, and on behalf of the EMMACE (Evaluation of Methods and
Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003
Eur. Heart J.,
March 1, 2007;
28(5):
540 - 545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Libby
Fat Fuels the Flame: Triglyceride-Rich Lipoproteins and Arterial Inflammation
Circ. Res.,
February 16, 2007;
100(3):
299 - 301.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. B. Keller and L. Lemberg
Secondary prevention of coronary artery disease in elderly persons: a treatise on a report by the american heart association.
Am. J. Crit. Care.,
September 1, 2006;
15(5):
514 - 518.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-C. Tardif, T. Heinonen, D. Orloff, and P. Libby
Vascular Biomarkers and Surrogates in Cardiovascular Disease
Circulation,
June 27, 2006;
113(25):
2936 - 2942.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
